Skip to content

Comparison of the effect of neostigmine, sufentanil, magnesium sulfate on controlling postoperative pain in patients candidates for transurethral resection of the prostate

Comparison of the effect of adding neostigmine, sufentanil and magnesium sulfate with intrathecal bupivacaine 0.5% on controlling postoperative pain in patients candidates for transurethral resection of the prostate (TURP)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20260509069314N1
Enrollment
144
Registered
2026-05-12
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia. Hyperplasia of prostate

Interventions

Intervention 1: First intervention group: Patients receiving a single 50 microgram dose of neostigmine (with the chemical composition of neostigmine methyl sulfate and 0.5 mg per ml, Caspian Tamin Pha

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients who are candidates for TURP and who are referred to Amir al-Momenin and Valiasr hospitals in Arak as elective procedures Patients in the age range of 30-70 years All patients with ASA class 1 and 2 Absence of heart, lung and liver diseases BMI less than or equal to 35 All TURP candidates undergoing spinal anesthesia Insensitivity to neostigmine, sufentanil and magnesium sulfate Maximum duration of surgery less than or equal to 90 minutes

Exclusion criteria

Exclusion criteria: All patients in whom spinal anesthesia fails for any reason and we have to resort to general anesthesia All patients whose surgery lasts more than 90 minutes Patients outside the age range of 30-70 All patients who experience cardiac and respiratory arrest during surgery

Design outcomes

Primary

MeasureTime frame
Average pain score in three groups. Timepoint: Recovery, 2, 4, 8, 12 and 24 hours after surgery. Method of measurement: Visual Analog Scale.

Secondary

MeasureTime frame
Shivering. Timepoint: Recovery. Method of measurement: Checklist; Binary Shivering asssessment.;Nausea and vomiting. Timepoint: Recovery. Method of measurement: Checklist; Binary Nausea and vomiting assessment.;Mean arterial pressure. Timepoint: Recovery. Method of measurement: Standard monitoring of vital signs in the operating room and recovery room.;Average heart rate. Timepoint: Recovery. Method of measurement: Standard operating room and recovery room cardiac monitoring and electrocardiogram.;Average of peripheral oxygen saturation. Timepoint: Recovery. Method of measurement: Pulse oximetry.;Average narcotic usage. Timepoint: 24 hours after surgery. Method of measurement: Medication registration checklist and patient file.;Average duration of pain relief. Timepoint: After surgery. Method of measurement: Recording the time of the patient's first request for narcotic and the patient's file.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Rasoul Jafari

Arak University of Medical Sciences

ra.jafari009@yahoo.com+98 68 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026